Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial

IMPORTANCE: The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) showed good safety and immunogenicity in phase 1 and 2 trials, but the clinical efficacy of the vaccine remains unknown. OBJECTIVE: To evaluate the efficacy and safety of a 2-dose regimen of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafavi, Ehsan, Eybpoosh, Sana, Karamouzian, Mohammad, Khalili, Malahat, Haji-Maghsoudi, Saiedeh, Salehi-Vaziri, Mostafa, Khamesipour, Ali, Jalali, Tahmineh, Nakhaeizadeh, Mehran, Sharifi, Hamid, Mansoori, Yasaman, Keramat, Fariba, Ghodrati, Samad, Javanian, Mostafa, Doroud, Delaram, Omrani, Mir Davood, Asadi, Hassan, Pouriayevali, Mohammad Hassan, Ghasemian, Roya, Farshidi, Hossein, Pourahmad, Morteza, Ghasemzadeh, Iman, Mounesan, Leila, Darvishian, Maryam, Mirjalili, Mohamad Reza, Toledo-Romani, Maria Eugenia, Valenzuela-Silva, Carmen, Verez-Bencomo, Vicente, Gouya, Mohammad Mehdi, Emadi-Koochak, Hamid, Haghdoost, Ali Akbar, Biglari, Alireza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157429/
https://www.ncbi.nlm.nih.gov/pubmed/37133864
http://dx.doi.org/10.1001/jamanetworkopen.2023.10302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157429/
https://www.ncbi.nlm.nih.gov/pubmed/37133864
http://dx.doi.org/10.1001/jamanetworkopen.2023.10302

Ejemplares similares